479PSafety profile of tepotinib in patients with advanced solid tumors: Pooled analysis of phase I and II data
ConclusionsTepotinib demonstrated an acceptable safety profile across a range of tumor types and is being developed in NSCLC as monotherapy and in combination. Further characterization of peripheral edema is ongoing. Table:479PN = 228Any Grade (≥10%)Grade ≥3 (≥2%)Any TRAE, n (%)172 (75.4)52 (22.8)Peripheral edema77 (33.8)8 (3.5)Diarrhea45 (19.7)4 (1.8)Fatigue34 (14.9)3 (1.3)Nausea29 (12.7)0 (0)Decreased appetite27 (11.8)0 (0)Increased lipase13 (5.7)9 (3.9)Increased AST11 (4.8)5 (2.2)Clinical trial identificationNCT01014936, NCT01832506, NCT01988493, NCT02115373, NCT02864992.Editorial acknowledgementMedical writi...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
260PPAM50 and CGH-array genomic characterization of HER2-equivocal breast cancers defined by the 2018 ASCO/CAP recommendations
ConclusionsUsing PAM50, the majority of HER2-equivocal cases were classified as Luminal tumors (Luminal B 52% and A 22%) and harbored mostly at the genomic level chr 17 segmental or large copy number gains. As there is no evidence of benefit of anti-HER2 therapy in these cases, it emphasizes the need of genomic status determination of HER2-equivocal cases.Legal entity responsible for the studyAnne Vincent-Salomon.FundingHas not received any funding.DisclosureP. Morel: Full / Part-time employment: Nanostring. H.A. Brauer: Full / Part-time employment: Nanosting. A. Vincent-Salomon: Advisory / Consultancy, Consulting fees: Ro...
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1599PThe relation between the symptom burden of hospitalized patients with incurable cancer and the quality-of-life of their family caregivers
ConclusionsThe high symptom burden experienced by patients with incurable cancer may have a negative impact on the QoL of their FCs, especially the physical aspect.Legal entity responsible for the studyClinical Oncology Department, Menofia University.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
261POncotypeDX ® predictive nomogram for recurrence score output: A machine learning system based on quantitative immunochemistry analysis - ADAPTED01
ConclusionsQuantitative IHC presents a good correlation with RS score in patients with RS ≤ 25, also in external validation set. A nomogram for physician that enhances a cost/effectiveness clinical approach practice has been developed. Prospective clinical application will be tested in further studies.Legal entity responsible for the studyFabio Marazzi.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
1601PClinical predictors for analgesic response to radiotherapy in patients with painful bone metastases
ConclusionsThis study supports previous findings that higher performance status, cancer diagnosis and higher baseline pain intensity predict analgesic RT response. The study presents new data showing that presence of soft tissue expansion predicts RT response and that CRP is not significantly associated with analgesic RT response.Clinical trial identificationNCT02107664 (Date of registration April 8, 2014).Legal entity responsible for the studyP ål Klepstad.FundingThe European Palliative Care Research Centre (PRC).DisclosureAll authors have declared no conflicts of interest. (Source: Annals of Oncology)
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research
